ADAR1 Capital Management LLC Acquires New Shares in Dynavax Technologies Corporation $DVAX

Key Points

• ADAR1 Capital Management LLC acquired a new stake in Dynavax Technologies by purchasing 170,000 shares valued at approximately $2.2 million during the first quarter.
• The company's stock had a market cap of $1.19 billion with a notable earnings report revealing earnings per share of $0.14, surpassing analysts' expectations.
• Dynavax Technologies has received a "Moderate Buy" rating from analysts, with a consensus target price of $24.33 amid various institutional investments.

ADAR1 Capital Management LLC purchased a new stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 170,000 shares of the biopharmaceutical company's stock, valued at approximately $2,205,000. ADAR1 Capital Management LLC owned approximately 0.14% of Dynavax Technologies at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Choreo LLC grew its position in shares of Dynavax Technologies by 3.2% during the first quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company's stock valued at $452,000 after purchasing an additional 1,065 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Dynavax Technologies by 4.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company's stock valued at $401,000 after buying an additional 1,453 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in Dynavax Technologies by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 220,980 shares of the biopharmaceutical company's stock valued at $2,822,000 after buying an additional 1,529 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Dynavax Technologies by 11.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 18,839 shares of the biopharmaceutical company's stock valued at $241,000 after buying an additional 1,966 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Dynavax Technologies by 2.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,796 shares of the biopharmaceutical company's stock worth $1,083,000 after acquiring an additional 2,206 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. JMP Securities reiterated a "market outperform" rating and set a $32.00 target price on shares of Dynavax Technologies in a research report on Friday, August 22nd. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Dynavax Technologies currently has a consensus rating of "Moderate Buy" and an average price target of $24.33.

Insider Activity at Dynavax Technologies

In related news, Director Scott Dunseth Myers purchased 3,800 shares of Dynavax Technologies stock in a transaction that occurred on Friday, August 22nd. The shares were bought at an average price of $10.82 per share, with a total value of $41,116.00. Following the purchase, the director directly owned 35,004 shares of the company's stock, valued at approximately $378,743.28. This represents a 12.18% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.98% of the company's stock.

Dynavax Technologies Trading Up 0.8%

Shares of Dynavax Technologies stock traded up $0.08 during trading on Friday, hitting $10.06. The stock had a trading volume of 1,421,965 shares, compared to its average volume of 1,905,858. Dynavax Technologies Corporation has a 12 month low of $9.22 and a 12 month high of $14.63. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. The firm's fifty day simple moving average is $10.63 and its 200-day simple moving average is $11.21. The stock has a market cap of $1.18 billion, a PE ratio of -21.87 and a beta of 1.24.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The business had revenue of $95.44 million during the quarter, compared to analyst estimates of $87.55 million. As a group, sell-side analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.